share_log

8-K: Cassava Sciences Resolves SEC Investigation

8-K: Cassava Sciences Resolves SEC Investigation

8-K:Cassava Sciences解決了SEC 調查
美股SEC公告 ·  09/27 07:39

Moomoo AI 已提取核心訊息

On September 26, 2024, Cassava Sciences, Inc., a biotechnology company focusing on Alzheimer's disease, announced a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the investigation into the company's disclosures about its Phase 2b clinical trial of simufilam for Alzheimer's treatment. The SEC had alleged that Cassava's disclosures contained materially misleading statements and omissions. Without admitting or denying the allegations, Cassava agreed to a permanent injunction against future violations and will pay a $40 million civil penalty. This settlement is pending final approval by a U.S. District Court. Cassava had previously reserved this amount for the potential settlement. Additionally, two former senior employees of Cassava settled with the SEC on related negligence-based disclosure charges. The...Show More
On September 26, 2024, Cassava Sciences, Inc., a biotechnology company focusing on Alzheimer's disease, announced a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the investigation into the company's disclosures about its Phase 2b clinical trial of simufilam for Alzheimer's treatment. The SEC had alleged that Cassava's disclosures contained materially misleading statements and omissions. Without admitting or denying the allegations, Cassava agreed to a permanent injunction against future violations and will pay a $40 million civil penalty. This settlement is pending final approval by a U.S. District Court. Cassava had previously reserved this amount for the potential settlement. Additionally, two former senior employees of Cassava settled with the SEC on related negligence-based disclosure charges. The company has also implemented remedial measures to enhance corporate governance. Cassava's CEO, Richard Barry, expressed relief at resolving the matter, allowing the company to focus on ongoing Phase 3 trials of simufilam. Cassava anticipates an operational cash use of $80 to $90 million for the second half of 2024, inclusive of the penalty, and estimates year-end cash balances to be between $117 to $127 million.
2024年9月26日,Cassava Sciences公司,一家專注於阿爾茨海默病的生物技術公司,宣佈與美國證券交易委員會(SEC)達成和解,涉及公司關於其阿爾茨海默病治療simufilam的第20期臨床試驗的披露進行的調查。SEC聲稱Cassava的披露包含實質性誤導性陳述和遺漏。在不承認或否認指控的情況下,Cassava同意永久禁令以防止未來違規行爲,並支付4000萬美元的民事罰款。該和解尚待美國地方法院最終批准。Cassava此前已爲潛在和解預留了這筆金額。此外,Cassava的兩名前高級僱員就相關失職披露指控與SEC達成了和解。公司還採取了補救措施以加強公司治理。Cassava的首席執行官Richard Barry對解決此事表示如釋重負,使該公司能夠專注於simufilam的正在進行中的第3期試驗。Cassava預計2024年下半年的運營現金支出爲8000萬至9億元,包括罰款,並估計年底現金餘額在1.17億至1.27億之間。
2024年9月26日,Cassava Sciences公司,一家專注於阿爾茨海默病的生物技術公司,宣佈與美國證券交易委員會(SEC)達成和解,涉及公司關於其阿爾茨海默病治療simufilam的第20期臨床試驗的披露進行的調查。SEC聲稱Cassava的披露包含實質性誤導性陳述和遺漏。在不承認或否認指控的情況下,Cassava同意永久禁令以防止未來違規行爲,並支付4000萬美元的民事罰款。該和解尚待美國地方法院最終批准。Cassava此前已爲潛在和解預留了這筆金額。此外,Cassava的兩名前高級僱員就相關失職披露指控與SEC達成了和解。公司還採取了補救措施以加強公司治理。Cassava的首席執行官Richard Barry對解決此事表示如釋重負,使該公司能夠專注於simufilam的正在進行中的第3期試驗。Cassava預計2024年下半年的運營現金支出爲8000萬至9億元,包括罰款,並估計年底現金餘額在1.17億至1.27億之間。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息